


# Stabilis



## Daunorubicin hydrochloride



Noms commerciaux

Cerubidin	Danemark, Grande Bretagne, Irlande, Norvège, Suède
Cerubidine	Belgique, Canada, Chili, Etats Unis d'Amérique, France, Luxembourg, Maroc, Pays bas, Suisse, Tunisie, Turquie
D Blastin	Maroc
Daunac	Colombie
Daunobin	Inde
Daunoblastin	Allemagne, Autriche
Daunoblastina	Arabie Saoudite, Espagne, Grèce, Hongrie, Iran, Italie, Vénézuëla
Daunocin	Inde, Malaisie, Pérou
Daunogobbi	Argentine
Daunomed	Inde, Pérou
Daunomycin	Inde
Daunoplus	Inde
Daunorubicin	Australie, Canada, Etats Unis d'Amérique, Grande Bretagne, Nouvelle Zélande
Daunorubicina	Chili, Colombie, Equateur, Mexique, Pérou
Daunorubitec	Inde
Daunoside	Inde
Daunotec	Inde, Vénézuëla
Daurocina	Chili
Epodoxo	Pérou
Maxidauno	Argentine, Equateur
Oncodaunotec	Colombie
Rubilem	Mexique
Runabicon	Colombie, Mexique
Zuleb	Mexique




















### Stabilité des solutions

PVC		0,016 mg/ml	4°C		7			148
PVC		0,02 mg/ml	22°C		48			1897

PVC		0,1 mg/ml	-20°C		43			686
PVC		0,1 mg/ml	22°C		8			1897
PVC		0,1 mg/ml	25°C		43			686
PVC		0,1 mg/ml	4°C		43			686
PVC		0,1 mg/ml	4°C		8			1897
PE		0,02 mg/ml	22°C		48			1897
PE		0,02 & 0,1 mg/ml	25°C		3			1520
PE		0,02 & 0,1 mg/ml	4°C		8			1520
PE		0,1 mg/ml	22°C		8			1897
PP		0,1 mg/ml	25°C		28			632
PP		0,0157 mg/ml	25°C		48			152
PP		0,0157 mg/ml	4°C		48			152
PP	RL	0,1 mg/ml	25°C		28			632
POF		0,4 >> 3 mg/ml	22°C		14			3438
POF		0,4 >> 3 mg/ml	4°C		14			3438
		2 mg/ml	4°C		43			686



### Stabilité en mélange

								
PVC		0,03 mg/ml	20°C		Cytarabine : 0,26 mg/ml Etoposide : 0,4 mg/ml	72		643
PP		0,0157 mg/ml	25°C		Etoposide : 0,157 mg/ml Cytarabine : 0,157 mg/ml	48		152
PP		0,0157 mg/ml	4°C		Etoposide : 0,157 mg/ml Cytarabine : 0,157 mg/ml	48		152











### Facteur influençant la stabilité

				1284
		< 0,5 mg/ml		1265



## Compatibilités

				
		Daunorubicin hydrochloride : 1 mg/ml Allopurinol sodium : 3 mg/ml		307
		Daunorubicin hydrochloride : 1 mg/ml Amifostine : 10 mg/ml		3
		Daunorubicin hydrochloride : 1 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Daunorubicin hydrochloride : 1 mg/ml Aztreonam : 40 mg/ml		99
		Daunorubicin hydrochloride : 1 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Daunorubicin hydrochloride Dexamethasone sodium phosphate		3668
		Daunorubicin hydrochloride Dexamethasone sodium phosphate		3604
		Daunorubicin hydrochloride : 1 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Daunorubicin hydrochloride : 1 mg/ml Filgrastim : 30 µg/ml		244
		Daunorubicin hydrochloride : 2 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Daunorubicin hydrochloride Fludarabine phosphate		3604
		Daunorubicin hydrochloride Fluorouracil		3474
		Daunorubicin hydrochloride : 1 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Daunorubicin hydrochloride Heparin sodium		3540
		Daunorubicin hydrochloride Heparin sodium		3604
		Daunorubicin hydrochloride Hydrocortisone sodium succinate		3604
		Daunorubicin hydrochloride : 1 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Daunorubicin hydrochloride : 1 mg/ml Melphalan : 0.1 mg/ml		169
		Daunorubicin hydrochloride : 0.52 mg/ml Methotrexate sodium : 30 mg/ml		150
		Daunorubicin hydrochloride Methylprednisolone acetate		3604
		Daunorubicin hydrochloride Methylprednisolone sodium succinate		3604
		Daunorubicin hydrochloride : 2 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Daunorubicin hydrochloride : 1 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Daunorubicin hydrochloride : 0.52 mg/ml Sodium bicarbonate : 14 mg/ml		150

	Daunorubicin hydrochloride : 1 mg/ml Teniposide : 0.1 mg/ml		905
	Daunorubicin hydrochloride : 1 mg/ml Thiotepa : 1 mg/ml		249
	Daunorubicin hydrochloride : 1 mg/ml Vinorelbine tartrate : 1 mg/ml		84
	Daunorubicin hydrochloride : 0.52 mg/ml		150



## Voie d'administration



## Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
148	Revue	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
150	Revue	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
152	Revue	Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J. Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion. Pharm Acta Helv 1995 ; 70: 141-148.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.

249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
632	Revue	Beijnen JH, Rosing H, De Vries PA, Underberg WJM. Stability of anthracycline antitumour agents in infusion fluids. J Parenter Sci Technol 1985 ; 39: 220-222.
643	Revue	Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR. In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep 1987 ; 71: 1189-1192.
686	Revue	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1265	Revue	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1284	Revue	Williams BA, Tritton TR. Photoinactivation of anthracyclines. Photochem Photobiol 1981 ; 34: 131-134.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1520	Laboratoire	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1897	Revue	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.

3438	Revue	Respaud R, Quenum L, Plichon C, Tournamille J.F, Gyan E, Antier D, Viaud-Massuard M.C. A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids. J Pharm Biomed Anal 2013 ; 83 : 164-170.
3474	Laboratoire	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3604	Laboratoire	Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012
3668	Laboratoire	Dexamethasone - Summary of Product Characteristics Hospira 2015



# Dictionnaire

	Anticancéreux		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyvinyl chlorure
	NaCl 0,9% ou glucose 5%		A l'abri de la lumière
	Jour		Lumière
	Heure		Non précisée
	Polyéthylène		Polypropylène
	Glucose 5%		Avec ou sans lumière
	Ringer lactate		Polyolefine
	Seringue polypropylène		Eau pour préparation injectable
	Stabilité en mélange		Solvant
	Molécule		NaCl 0,45% Glucose 5%
	Facteur influençant la stabilité		Provoque
	Dégradation		Compatibilités
	Turbidité immédiate		Incompatible
	Chlorure de sodium 0,9%		Compatible
	Incompatibilité non précisée		Précipitation immédiate
	Changement de couleur à 4 heures		Aucun
	NaHCO <sub>3</sub>		Voie d'administration
	Intraveineuse		Perfusion intraveineuse
	Bibliographie		Dictionnaire